173 related articles for article (PubMed ID: 18581278)
1. SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation.
Heebøll S; Borre M; Ottosen PD; Andersen CL; Mansilla F; Dyrskjøt L; Orntoft TF; Tørring N
Histol Histopathol; 2008 Sep; 23(9):1069-76. PubMed ID: 18581278
[TBL] [Abstract][Full Text] [Related]
2. Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure.
Hansen RL; Heeboll S; Ottosen PD; Dyrskjøt L; Borre M
Scand J Urol Nephrol; 2011 Mar; 45(2):91-6. PubMed ID: 21087120
[TBL] [Abstract][Full Text] [Related]
3. Snail1 is over-expressed in prostate cancer.
Heebøll S; Borre M; Ottosen PD; Dyrskjøt L; Orntoft TF; Tørring N
APMIS; 2009 Mar; 117(3):196-204. PubMed ID: 19245592
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
5. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of potential therapeutic targets in prostate cancer.
Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
De Marzo AM; Meeker AK; Epstein JI; Coffey DS
Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
[TBL] [Abstract][Full Text] [Related]
8. Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer.
Yuen HF; Chua CW; Chan YP; Wong YC; Wang X; Chan KW
Histopathology; 2007 Apr; 50(5):648-58. PubMed ID: 17394502
[TBL] [Abstract][Full Text] [Related]
9. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
Pérez-Martínez FC; Alonso V; Sarasa JL; Manzarbeitia F; Vela-Navarrete R; Calahorra FJ; Esbrit P
Histol Histopathol; 2008 Jun; 23(6):709-15. PubMed ID: 18366009
[TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
13. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
14. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
15. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
16. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
[TBL] [Abstract][Full Text] [Related]
17. CIP2A expression in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue mıcroarray study.
Celikden SG; Baspinar S; Ozturk SA; Karaibrahimoglu A
Malays J Pathol; 2020 Aug; 42(2):227-236. PubMed ID: 32860375
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor status of lymph node metastases from prostate cancer.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
[TBL] [Abstract][Full Text] [Related]
20. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Srivastava S; Oelschlager DK; Grizzle WE
J Natl Cancer Inst; 1994 Aug; 86(15):1140-5. PubMed ID: 7913137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
